Generation of recombinant vaccinia viruses via green fluorescent protein selection

DNA and Cell Biology

Volumn 28, Issue 3, 2009, Pages 103-108

  Popov, Sergei ^a,b   Mirshahidi, Saied ^a,b   Essono, Sosthène ^a,b   Song, Ruijiang ^a,b   Wang, Xiaowei ^a,b   Ruprecht, Ruth M ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BROXURIDINE; GREEN FLUORESCENT PROTEIN; RECOMBINANT PROTEIN; THYMIDINE KINASE; VIRUS VECTOR;

ARTICLE; CONTROLLED STUDY; EMBRYO; ENVELOPE GENE; FLOW CYTOMETRY; GENE; GENE SEQUENCE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; INTERNAL RIBOSOME ENTRY SITE; MICROSCOPE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; VACCINIA VIRUS; WILD TYPE;

CELL LINE; FLOW CYTOMETRY; GENES, ENV; GREEN FLUORESCENT PROTEINS; HIV; HUMANS; PROTEIN ENGINEERING; RECOMBINANT PROTEINS; THYMIDINE KINASE; VACCINIA VIRUS; VIRAL PROTEINS;

HUMAN IMMUNODEFICIENCY VIRUS; VACCINIA VIRUS;

EID: 62249214234     PISSN: 10445498     EISSN: None     Source Type: Journal    
DOI: 10.1089/dna.2008.0792     Document Type: Article

References (25)

1. Bleckwenn, N.A., Bentley, W.E., and Shiloach, J. (2003). Exploring vaccinia virus as a tool for large-scale recombinant protein expression. Biotechnol Prog 19, 130-136.
2. Borman, A.M., Le Mercier, P., Girard, M., and Kean, K.M. (1997). Comparison of picornaviral IRES-driven internal initiation of translation in cultured cells of different origins. Nucleic Acids Res 25, 925-932.
3. Chakrabarti, S., Sisler, J.R., and Moss, B. (1997). Compact, synthetic, vaccinia virus early/late promoter for protein expression. Biotechniques 23, 1094-1097.
4. Davison, A.J., and Moss, B. (1989a). Structure of vaccinia virus early promoters. J Mol Biol 210, 749-769.
5. Davison, A.J., and Moss, B. (1989b). Structure of vaccinia virus late promoters. J Mol Biol 210, 771-784.
6. Dominguez, J., Lorenzo, M.M., and Blasco, R. (1998). Green fluorescent protein expressed by a recombinant vaccinia virus permits early detection of infected cells by flow cytometry. J Immunol Methods 220, 115-121.
7. Doria-Rose, N.A., Ohlen, C., Polacino, P., Pierce, C.C., Hensel, M.T., Kuller, L., Mulvania, T., Anderson, D., Greenberg, P.D., Hu, S.L., and Haigwood, N.L. (2003). Multigene DNA priming-boosting vaccines protect macaques from acute CD4+-T-cell depletion after simian-human immunodeficiency virus SHIV89.6P mucosal challenge. J Virol 77, 11563-11577.
8. Earl, P.L., Broder, C.C., Long, D., Lee, S.A., Peterson, J., Chakrabarti, S., Doms, R.W., and Moss, B. (1994). Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities. J Virol 68, 3015-3026.
9. Edghill-Smith, Y., Golding, H., Manischewitz, J., King, L.R., Scott, D., Bray, M., Nalca, A., Hooper, J.W., Whitehouse, C.A., Schmitz, J.E., Reimann, K.A., and Franchini, G. (2005). Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus. Nat Med 11, 740-747.
10. Gaines, P., and Wojchowski, D.M. (1999). pIRES-CD4t, a dicistronic expression vector for MACS- or FACS-based selection of transfected cells. Biotechniques 26, 683-688.
11. Grisson, R.D., Chenine, A.L., Yeh, L.Y., He, J., Wood, C., Bhat, G.J., Xu, W., Kankasa, C., and Ruprecht, R.M. (2004). Infectious molecular clone of a recently transmitted pediatric human immunodeficiency virus clade C isolate from Africa: evidence of intraclade recombination. J Virol 78, 14066-14069.
12. Hu, S.L., Abrams, K., Barber, G.N., Moran, P., Zarling, J.M., Langlois, A.J., Kuller, L., Morton, W.R., and Benveniste, R.E. (1992). Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160. Science 255, 456-459.
13. Li, Y., Cleveland, B., Klots, I., Travis, B., Richardson, B.A., Anderson, D., Montefiori, D., Polacino, P., and Hu, S.L. (2008). Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responses. J Virol 82, 638-651.
14. Lorenzo, M.M., Galindo, I., and Blasco, R. (2004). Construction and isolation of recombinant vaccinia virus using genetic markers. Methods Mol Biol 269, 15-30.
15. Mackett, M., Smith, G.L., and Moss, B. (1984). General method for production and selection of infectious vaccinia virus recombinants expressing foreign genes. J Virol 49, 857-864.
16. Moss, B. (1996). Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc Natl Acad Sci USA 93, 11341-11348.
17. Moss, B., and Earl, P.L. (2001). Overview of the vaccinia virus expression system. Curr Protoc Protein Sci Chapter 5, Unit5.11.
18. Norbury, C.C., Malide, D., Gibbs, J.S., Bennink, J.R., and Yewdell, J.W. (2002). Visualizing priming of virus-specific CD8+T cells by infected dendritic cells in vivo. Nat Immunol 3, 265-271.
19. Popov, S., Chenine, A.L., Gruber, A., Li, P.L., and Ruprecht, R.M. (2005). Long-term productive human immunodeficiency virus infection of CD1a-sorted myeloid dendritic cells. J Virol 79, 602-608.
20. Qutaishat, S.S., and Olson, J.L. (2003). Bioterrorism preparedness: the smallpox vaccine debate. Clin Med Res 1, 85-86.
21. Rasmussen, R.A., Ong, H., Kittel, C., Ruprecht, C.R., Ferrantelli, F., Hu, S.L., Polacino, P., McKenna, J., Moon, J., Travis, B., and Ruprecht, R.M. (2006). DNA prime/protein boost immunization against HIV clade C: safety and immunogenicity in mice. Vaccine 24, 2324-2332.
22. Song, R.J., Chenine, A.L., Rasmussen, R.A., Ruprecht, C.R., Mirshahidi, S., Grisson, R.D., Xu, W., Whitney, J.B., Goins, L.M., Ong, H., Li, P.L., Shai-Kobiler, E., Wang, T., McCann, C.M., Zhang, H., Wood, C., Kankasa, C., Secor, W.E., McClure, H.M., Strobert, E., Else, J.G., and Ruprecht, R.M. (2006). Molecularly cloned SHIV-1157ipd3N4: a highly replication-competent, mucosally transmissible R5 simian-human immunodeficiency virus encoding HIV clade C Env. J Virol 80, 8729-8738.
23. Stanford, M.M., and McFadden, G. (2005). The "supervirus"? Lessons from IL-4-expressing poxviruses. Trends Immunol 26, 339-345.
24. Terajima, M., Van Epps, H.L., Li, D., Leporati, A.M., Juhlin, S.E., Mustonen, J., Vaheri, A., and Ennis, F.A. (2002). Generation of recombinant vaccinia viruses expressing Puumala virus proteins and use in isolating cytotoxic T cells specific for Puumala virus. Virus Res 84, 67-77.
25. Zhan, X., Martin, L.N., Slobod, K.S., Coleclough, C., Lockey, T.D., Brown, S.A., Stambas, J., Bonsignori, M., Sealy, R.E., Blanchard, J.L., and Hurwitz, J.L. (2005). Multi-envelope HIV-1 vaccine devoid of SIV components controls disease in macaques challenged with heterologous pathogenic SHIV. Vaccine 23, 5306-5320.